Six Part B drugs were the first ever selected for Medicare drug price negotiation. Starting 2028-01-01, Medicare's benchmark for each stops being ASP + 6% and becomes 106% of a negotiated Maximum Fair Price (MFP) — a number CMS sets, not a market rate. This table is the commercial baseline for all six, captured while ASP + 6% is still the rule everywhere, commercial and Medicare alike.
Selected 2026-01-27. Median index is the middle insurer's contracted rate as a multiple of ASP × 100. p10/p90 mark the 10th–90th percentile spread across insurers on the same scale.
| Drug | Insurers | Median index | p10 | p90 | $/unit | Part B spend |
|---|---|---|---|---|---|---|
| Orencia (abatacept) J0129 |
58 | 97.6 | 96.2 | 121.2 | $44.77 | $718M |
| Entyvio (vedolizumab) J3380 |
59 | 98.8 | 97.0 | 122.4 | $21.37 | $574M |
| Xolair (omalizumab) J2357 |
58 | 97.7 | 89.8 | 110.5 | $45.50 | $316M |
| Botox (onabotulinumtoxinA) J0585 |
59 | 100.1 | 96.2 | 120.0 | $6.51 | $395M |
| Cimzia (certolizumab pegol) J0717 |
57 | 113.5 | 110.0 | 220.0 | $3.91 | $274M |
| Cosentyx (secukinumab) J3247 |
50 | 99.1 | 97.8 | 112.2 | $18.07 | $127M |
This is the only public commercial baseline for these six drugs captured before MFP takes effect. Once 106% of MFP replaces ASP+6% as the Medicare benchmark on 2028-01-01, comparing commercial contracts to "Medicare" will mean comparing them to a negotiated government price instead of a statutory markup on a market price — a different kind of number. This table is the record of what commercial insurers were actually paying, relative to ASP, in the last vintage before that change.
Contracted rates from insurers’ machine-readable files, not amounts paid on a claim. Figures are drawn from report_data.json published alongside the Infusion Reimbursement Index and are not independently re-derived on this page.